TAK Overview
Upcoming Projects (TAK)
-
Analyzing the Phase 3 VERIFY Trial Results for Rusfertide (PTG-300) in Polycythemia Vera from Protagonist and Takeda
Tickers: PTGX, TAK
Execute By: Aug 31, 2025
Executed Projects (TAK)
-
Quarterly Survey: Depression Bipolar Disorder Treatments & AXSM's Auvelity and ITCI's Caplyta January 2025
Tickers: AXSM, ITCI, TAK
Executed On: Jan 28, 2025 at 11:00 AM EST -
Quarterly Survey: Depression Bipolar Disorder Treatments & AXSM's Auvelity and ITCI's Caplyta October 2024
Tickers: AXSM, ITCI, TAK
Executed On: Oct 18, 2024 at 03:03 PM EDT -
Quarterly Survey: Depression Bipolar Disorder Treatments & AXSM's Auvelity and ITCI's Caplyta July 2024
Tickers: AXSM, ITCI, TAK
Executed On: Jul 31, 2024 at 01:02 PM EDT -
Discussing the recent data from Takeda's phase 2b trial of TAK-861 as a treatment for patients with narcolepsy.
Tickers: TAK, JAZZ
Executed On: Jun 07, 2024 at 12:00 PM EDT -
Quarterly Survey: Depression Bipolar Disorder Treatments and AXSM's Auvelity and ITCI's Caplyta April 2024
Tickers: AXSM, ITCI, TAK
Executed On: Apr 18, 2024 at 12:59 PM EDT -
Quarterly Survey: Depression Bipolar Disorder Treatments and AXSM's Auvelity and ITCI's Caplyta January 2024
Tickers: AXSM, ITCI, TAK
Executed On: Jan 19, 2024 at 02:45 PM EST -
A Second Opinion: Interpreting both Alkermes’ ALKS-2680 and Takeda’s TAK-861 initial data for narcolepsy and how the OX2R class may ultimately fit in the treatment paradigm
Tickers: ALKS, TAK, CNTA
Executed On: Dec 08, 2023 at 09:30 AM EST -
Interpreting both Alkermes’ ALKS-2680 and Takeda’s TAK-861 initial data for narcolepsy and how the OX2R class may ultimately fit in the treatment paradigm
Tickers: ALKS, TAK, CNTA
Executed On: Nov 27, 2023 at 01:30 PM EST -
Quarterly Survey: Depression Bipolar Disorder Treatments and AXSM's Auvelity and ITCI's Caplyta October 2023
Tickers: AXSM, ITCI, TAK
Executed On: Nov 03, 2023 at 01:07 PM EDT -
Looking into the phase 3 FRESCO-2 clinical trial data on fruquintinib in patients with refractory metastatic colorectal cancer.
Ticker: TAK
Executed On: Jul 20, 2023 at 03:15 PM EDT -
Examining the potential of Takeda's enzyme replacement therapy, TAK-755 in treating congenital thrombotic thrombocytopenic purpura (cTTP)
Ticker: TAK
Executed On: Jan 24, 2023 at 01:00 PM EST -
Discussing the potential of Takeda's Dengue Vaccine candidate, QDENGA, and Valneva SE's single-shot Chikungunya Vaccine candidate, VLA1553
Tickers: TAK, VALN
Executed On: Dec 21, 2022 at 02:45 PM EST -
A Second Perspective: Discussing a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 04, 2022 at 11:00 AM EST -
A discussion around a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 01, 2022 at 02:00 PM EST -
A Second Look: What's the potential of NMTR's Vurolenatide in short bowel syndrome?
Tickers: NMTR, TAK
Executed On: Jan 06, 2022 at 01:30 PM EST
Upcoming & Overdue Catalysts (TAK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TAK)
Strategic Initiatives (TAK)
-
Takeda Pharmaceutical Co(TAK) to sell eye drug Xiidra to Novartis AG(NVS)
Tickers: NVS, TAK
Announcement Date: May 08, 2019
